Research Using the MOATT
A Structured Nursing Intervention at Dana-Farber Cancer Institute
Jean Boucher and colleagues published the results of a study designed to evaluate a nurse-led intervention using the MOATT with the goals of increasing patient knowledge and adherence to therapy. This was a longitudinal, descriptive, feasibility study conducted in an ambulatory thoracic oncology disease center at the Dana-Farber Cancer Institute in Boston, Massachusetts. Thirty adult patients with lung cancer, who were being treated with the oral agent erlotinib, participated in the study (with 27 completing).
The Kansas Medical Assistance Program (KMAP) has created a preferred drug list (PDL) to promote clinically appropriate utilization of pharmaceuticals in a cost-effective manner without compromising the quality of care. The Kansas Medicaid PDL was authorized by . 39-7,121a, allowing KMAP to develop a PDL based on safety, effectiveness and clinical outcomes. If these factors indicate no therapeutic advantage among the drugs being considered in the same drug class, then KMAP considers the net economic impact (lowest net cost to the State) of such drugs when recommending drugs for inclusion in the Medicaid PDL. The statute states that "drugs which do not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness or clinical outcomes may be excluded from the preferred drug formulary and be subject to prior authorization in accordance with state and federal laws."